

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Natalie Davis Examiner #: 78462 Date: 4-22-01
 Art Unit: 1642 Phone Number 308-6410 Serial Number: 091717883
 Mail Box and Bldg/Room Location: 8E12 CM1 4C01 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: _____

Inventors (please provide full names): _____

Earliest Priority Filing Date: 11-22-99

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please search Ovr 107 for its use in the diagnosis, staging, monitoring + treatment of cancers. Also, on antibody to Ovr 107. Also ~~Seq 1070.1~~ cancelled no CRF data

nothing in
get pat info.
no pat. no. in Palm

STAFF USE ONLY**Type of Search****Vendors and cost where applicable**

Searcher: _____ Point of Contact: _____ NA Sequence (#) _____ STN _____
 Searcher Phone #: _____ Alex Wacławiw _____ AA Sequence (#) _____ Dialog _____
 Searcher Location: _____ Technical Info. Specialist _____ Structure (#) _____ Questel/Orbit _____
 Date Searcher Picked Up: 5-3 Bibliographic _____ Dr. Link _____
 Date Completed: 5-3 Litigation _____ Lexis/Nexis _____
 Searcher Prep & Review Time: 8 Fulltext _____ Sequence Systems _____
 Clerical Prep Time: _____ Patent Family _____ WWW/Internet _____
 Online Time: 31 Other _____ Other (specify) _____

Davis 09/717,883

HILIGHT set on as ''
HILIGHT set on as ''
?

03may01 13:51:42 User035515 Session D451.2
\$0.00 0.056 DialUnits File410
\$0.00 Estimated cost File410
\$0.00 Estimated cost this search
\$0.66 Estimated total session cost 0.229 DialUnits
SYSTEM:HOME
Menu System II: D2 version 1.7.8 term=ASCII
*** DIALOG HOMEBASE(SM) Main Menu ***

Information:

1. Announcements (new files, reloads, etc.)
2. Database, Rates, & Command Descriptions
3. Help in Choosing Databases for Your Topic
4. Customer Services (telephone assistance, training, seminars, etc.)
5. Product Descriptions

Connections:

6. DIALOG(R) Document Delivery
7. Data Star(R)

(c) 2000 The Dialog Corporation plc All rights reserved.

/H = Help

/L = Logoff

/NOMENU = Command Mode

Enter an option number to view information or to connect to an online service. Enter a BEGIN command plus a file number to search a database (e.g., B1 for ERIC).

? b 411

03may01 13:51:53 User035515 Session D451.3
\$0.00 0.164 DialUnits FileHomeBase
\$0.00 Estimated cost FileHomeBase
\$0.01 TYMNET
\$0.01 Estimated cost this search
\$0.67 Estimated total session cost 0.394 DialUnits
File 411:DIALINDEX(R)

DIALINDEX(R)

(c) 2001 The Dialog Corporation plc

*** DIALINDEX search results display in an abbreviated ***
*** format unless you enter the SET DETAIL ON command. ***

? sf all

You have 576 files in your file list.

(To see banners, use SHOW FILES command)

? s ovr107 or ovr()107

Your SELECT statement is:

s ovr107 or ovr()107


Davis 09/717,883


Items	File
Examined 50 files	
Examined 100 files	
Examined 150 files	
Examined 200 files	
Examined 250 files	
Examined 300 files	
Examined 350 files	
Examined 400 files	
Examined 450 files	
Examined 500 files	
Examined 550 files	

No files have one or more items; file list includes 576 files.



(FILE 'WPIDS' ENTERED AT 14:27:14 ON 03 MAY 2001)
DEL HIS Y

FILE 'MEDLINE, BIOSIS, WPIDS, EMBASE' ENTERED AT 14:29:11 ON 03 MAY 2001

L1 0 S OVR107
L2 0 S OVR 017
L3 105 S OVR
L4 106461 S (CANCER OR TUMOR OR TUMOUR) (L) MARKER#
L5 0 S L3 AND L4
L6 3080636 S (CANCER OR TUMOR OR TUMOUR OR NEOPLAS?)
L7 3 S L6 AND L3
L8 3 DUP REM L7 (0 DUPLICATES REMOVED)

=> d bib ab 1-3

L8 ANSWER 1 OF 3 MEDLINE
AN 2000172713 MEDLINE
DN 20172713 PubMed ID: 10707722
TI Distal fibular giant cell **tumour**.
AU Dogra A S; Kulkarni S S; Bhosale P B
CS Department of Orthopaedics, Seth G S Medical College, Parel, Mumbai.
SO JOURNAL OF POSTGRADUATE MEDICINE, (1995 Jul-Sep) 41 (3) 83-4.
Journal code: JS7; 2985196R. ISSN: 0022-3859.
CY India
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200003
ED Entered STN: 20000330
Last Updated on STN: 20000330
Entered Medline: 20000323
AB A patient who reported with a slowly growing swelling **ovr** thee
lateral aspect of the left ankle, was investigated and diagnosed to have
a
giant cell **tumour** which was confirmed on FNAC. The
tumour was managed with excision biopsy and reconstruction. The
case is being reported for its rare site of occurrence.

L8 ANSWER 2 OF 3 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 1993-182210 [22] WPIDS
DNC C1993-080645
TI Extending vascular dwell time of therapeutic and diagnostic agents - by
adjunct admin. with dwell time enhancing agent.
DC B05 B07 D16
IN LONG, D M; LONG, R A
PA (LONG-I) LONG D M; (LONG-I) LONG R A
CYC 38
PI WO 9309762 A2 19930527 (199322)* EN 62p
RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL OA SE
W: AU BB BG BR CA CS FI HU JP KR LK MG MN MW NO PL RO RU SD UA
AU 9230712 A 19930615 (199340)
US 5264220 A 19931123 (199348) 16p
EP 612240 A1 19940831 (199433) EN

R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE
 US 5391376 A 19950221 (199513) 17p
 WO 9309762 A3 19930624 (199513)
 JP 07505127 W 19950608 (199531)
 EP 612240 A4 19950517 (199615)
 US 5679394 A 19971021 (199748) 15p
 ADT WO 9309762 A2 WO 1992-US9660 19921112; AU 9230712 A AU 1992-30712
 19921112; US 5264220 A US 1991-790855 19911112; EP 612240 A1 EP
 1992-924382 19921112, WO 1992-US9660 19921112; US 5391376 A Div ex US
 1991-790855 19911112, US 1993-122192 19930915; WO 9309762 A3 WO
 1992-US9660 19921112; JP 07505127 W WO 1992-US9660 19921112, JP
 1993-509361 19921112; EP 612240 A4 EP 1992-924382 ; US 5679394 A
 Div ex US 1991-790855 19911112, Div ex US 1993-122192 19930915, US
 1995-379249 19950127
 FDT AU 9230712 A Based on WO 9309762; EP 612240 A1 Based on WO 9309762; US
 5391376 A Div ex US 5264220; JP 07505127 W Based on WO 9309762; US
 5679394
 A Div ex US 5264220, Div ex US 5391376
 PRAI US 1991-790855 19911112; US 1993-122192 19930915; US 1995-379249
 19950127
 AB WO 9309762 A UPAB: 19931115
 Method for deliverng a particulate therapeutic or diagnostic agent (PTDA)
 via the vascular compartment of a mammal, comprising the adjunct admin.
 of
 the above agent and a vascular dwell-time enhancing agent (VDTEA),
 provided that the PTDA is not a particulate blood substitute (PBS), is
 new.
 Method for delivering a PBS via the vascular compartment of a
 mammal,
 comprising the adjunct admin. of the PBS and VDTEA, is new.
 Method for preventing or treating cachexia in a mammal, comprising
 admin. of an anti-cachexia agent, is new.
 USE/ADVANTAGE - The VDTEA retard phago- and pino-cytosis, which
 causes removal of the PTDA by metabolism and excretion via the RES, so
 that the time that agents can express their efficiency is increased.
 Side-effects traceable to phagocytosis causing cytokine and eicosanoid
 (TNF, IL-1, PGE-2, thromboxane A-2) release are also reduced e.g, fever,
 back pain, and pulmonary hypertension. Phagocytosis is esp. marked for
 particulates of 0.001-50 microns dia. The VDTEA also enhance the
 stability, of the carrier system used for the agent, retarding
 metabolism. Therapeutic particulates include chemotherapeutic agents,
 vasopressors, antiinflammatories, anaesthetics, vasodilator,
 tranquilliser, soporific, or sedatives, provided. Uses of VDTEA with PBS
 include prevention and treatment of hypoxia in non-neoplastic
 cell (e.g, during any surgical procedure with compromised blood
 circulation and perfusion, including angioplasty or heart-lung by-pass),
 other hypoxia, or anaemia. A partic. use is in treatment of
 neoplastic tissue, in which the tissue need not be immediately
 irradiated, e.g, ovr 3 hr., pref. up to 48-72 hr. after the
 adjunct admin.
 Dwg.0/0
 L8 ANSWER 3 OF 3 BIOSIS COPYRIGHT 2001 BIOSIS
 AN 1989:478708 BIOSIS
 DN BA88:114468
 TI CANCER MORTALITY IN A NORTHERN ITALIAN COHORT OF RUBBER WORKERS.
 AU NEGRI E; PIOLATTO G; PIRA E; DECARLI A; KALDOR J; LA VECCHIA C

CS MARIO NEGRI, INST. PHARMACOLOGICAL RES., 20157 MILAN, ITALY.
SO BR J IND MED, (1989) 46 (9), 624-628.
CODEN: BJIMAG. ISSN: 0007-1072.
FS BA; OLD
LA English
AB An analysis of the mortality of a cohort of 6629 workers employed from 1906 to 1981 in a rubber tire factor in northern Italy (978 deaths and over 133,000 man-years at risk) showed that the all cause mortality ratio was slightly lower than expected (0.91). Overall **cancer** mortality was close to expected (275 v 259.4) but there were significant excess rates for two **cancer** sites: pleura (9 observed v 0.8 expected, which may be due to the use of fibre containing talc) and bladder (16 observed v 8.8 expected). Death rates were not raised for other sites previously associated with employment in the rubber industry, such as cancers of the lung and brain, leukaemias, or lymphomas. The substantially reduced relative risk of pleural **cancer** among workers first employed after 1940 (RR = 0.05 compared with before 1940) probably reflected improvements in working conditions over more recent periods. For **cancer** of the bladder, the relative risk was also lower for workers first engaged after 1940. Thus no appreciable risk for any disease was apparent for workers employed over the past four decades. Analysis for each of the 27 job categories showed a substantial excess for **cancer** of the pleura in the mechanical maintenance workers (4 observed v 0.17 expected); an excess of **cancer** of the lung (21 v 13.48) was also present in this job category.

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 14:35:07 ON 03 MAY 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1947 - 3 May 2001 VOL 134 ISS 19
FILE LAST UPDATED: 2 May 2001 (20010502/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

HCAplus now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

=> d his 19-

(FILE 'MEDLINE, BIOSIS, WPIDS, EMBASE' ENTERED AT 14:29:11 ON 03 MAY 2001)

FILE 'HCAPLUS' ENTERED AT 14:33:22 ON 03 MAY 2001

SET SFIELD BI
 L9 0 S OVR107 OR OVR 107
 L10 18 S OVR
 L11 581450 S CANCER# OR TUMOR# OR NEOPLAS? OR METAST? OR MARKER#
 L12 ~~2 S L10 AND L11~~

FILE 'HCAPLUS' ENTERED AT 14:35:07 ON 03 MAY 2001

=> d .ca 1-2

L12 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2000:161492 HCAPLUS

DOCUMENT NUMBER: 132:204018

TITLE: Diagnosis and staging of various **cancers** by detection of **cancer**-specific genes (CSG) and antibody-based treatment

INVENTOR(S): Salceda, Susana; Sun, Yongming; Recipon, Herve; Cafferkey, Robert

PATENT ASSIGNEE(S): Diadexus Llc, USA

SOURCE: PCT Int. Appl., 58 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000012758	A1	20000309	WO 1999-US19655	19990901
W: CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				

PRIORITY APPLN. INFO.: US 1998-98880 19980902

AB The present invention provides a new method for detecting, diagnosing, monitoring, staging, and prognosticating selected **cancers** including gynecol. **cancers** such as breast, ovarian, uterine and endometrial **cancer** and lung **cancer** by measurement of the levels of **cancer**-specific genes (CSG) in cells, tissue, or bodily fluid of a control patient and in a **cancer** patient, where elevated CSG levels indicated the presence of **cancer**, and further elevated levels the occurrence of **metastasis**. **Cancer**-specific gene sequences are presented which may be used as diagnostic **markers** for the presence of CSG. Antibodies to these sequences labeled with paramagnetic ions or radioisotopes may be used for imaging the **cancer**, and antibodies conjugated to cytotoxic agents may be used therapeutically.

IC ICM C12Q001-68

ICS C07K016-8

CC 3-1 (Biochemical Genetics)

Section cross-reference(s): 14

ST diagnosis staging imaging **cancer** CSG gene detection antibody
IT Gene, animal
RL: ADV (Adverse effect, including toxicity); ANT (Analyte); BOC
(Biological occurrence); ANST (Analytical study); BIOL (Biological
study);
OCCU (Occurrence)
(CSG; diagnosis and staging of various **cancers** by detection
of **cancer**-specific genes (CSG) and antibody-based treatment)
IT Proteins, specific or class
RL: ADV (Adverse effect, including toxicity); ANT (Analyte); BOC
(Biological occurrence); ANST (Analytical study); BIOL (Biological
study);
OCCU (Occurrence)
(Ovr; **cancer marker**; diagnosis and
staging of various **cancers** by detection of **cancer**
-specific genes (CSG) and antibody-based treatment)
IT Antitumor agents
(anti-CSG conjugates; diagnosis and staging of various **cancers**
by detection of **cancer**-specific genes (CSG) and
antibody-based treatment)
IT Antibodies
RL: ARG (Analytical reagent use); BUU (Biological use, unclassified);
ANST
(Analytical study); BIOL (Biological study); USES (Uses)
(anti-CSG; labeled and cytotoxin-conjugated; diagnosis and staging of
various **cancers** by detection of **cancer**-specific
genes (CSG) and antibody-based treatment)
IT DNA sequences
Lung, **neoplasm**
Neoplasm
Ovary, **neoplasm**
Tumor markers
(diagnosis and staging of various **cancers** by detection of
cancer-specific genes (CSG) and antibody-based treatment)
IT Uterus, **neoplasm**
(endometrium; diagnosis and staging of various **cancers** by
detection of **cancer**-specific genes (CSG) and antibody-based
treatment)
IT **Neoplasm**
(**metastasis**; diagnosis and staging of various **cancers**
by detection of **cancer**-specific genes (CSG) and
antibody-based treatment)
IT Diagnosis
(mol.; diagnosis and staging of various **cancers** by detection
of **cancer**-specific genes (CSG) and antibody-based treatment)
IT Mammary gland
(**neoplasm**; diagnosis and staging of various **cancers**
by detection of **cancer**-specific genes (CSG) and
antibody-based treatment)
IT 197982-63-1
RL: ADV (Adverse effect, including toxicity); ANT (Analyte); BOC
(Biological occurrence); ANST (Analytical study); BIOL (Biological
study);
OCCU (Occurrence)
(amino acid sequence; diagnosis and staging of various **cancers**
by detection of **cancer**-specific genes (CSG) and
antibody-based treatment)

IT 198056-06-3, GenBank U75329
 RL: ADV (Adverse effect, including toxicity); ANT (Analyte); BOC
 (Biological occurrence); ANST (Analytical study); BIOL (Biological
 study);

OCCU (Occurrence)

(diagnosis and staging of various **cancers** by detection of
cancer-specific genes (CSG) and antibody-based treatment)

IT 260425-01-2 260425-02-3 260425-03-4 260425-04-5 260425-05-6, DNA
 (human **cancer**-specific gene 255687) 260425-06-7, DNA (human
cancer-specific gene 251313) 260425-07-8, DNA (human
cancer-specific gene 12029) 260425-08-9, DNA (human
cancer-specific gene 251804) 260425-09-0 260425-10-3
 260425-11-4 260425-12-5 260425-13-6

RL: ADV (Adverse effect, including toxicity); ANT (Analyte); BOC
 (Biological occurrence); ANST (Analytical study); BIOL (Biological
 study);

OCCU (Occurrence)

(nucleotide sequence; diagnosis and staging of various **cancers**
 by detection of **cancer**-specific genes (CSG) and
 antibody-based treatment)

REFERENCE COUNT:

3

REFERENCE(S):

- (1) Croce; US 5939258 A 1999 HCAPLUS
- (2) Paoloni-Giacobino; Genomics 1997, V44, P309
- (3) Yu; US 5733748 A 1998 HCAPLUS

L12 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1995:650895 HCAPLUS

TITLE: Phase I study and clinical pharmacological evaluation
 of daily oral etoposide combined with carboplatin in
 patients with lung **cancer**

AUTHOR(S): Ohune, Terumasa; Fujiwara, Yasuhiro; Sumiyoshi,
 Hidetaka; Yamaoka, Naoki; Yamakido, Michio

CORPORATE SOURCE: Department Internal Medicine, Hiroshima Univ. School
 Medicine, Hiroshima, 734, Japan

SOURCE: Jpn. J. Cancer Res. (1995), 86(5), 490-500

CODEN: JJCREP; ISSN: 0910-5050

DOCUMENT TYPE:

Journal

LANGUAGE:

English

AB Twenty-eight patients with inoperable or relapsed lung **cancer**
 were given a combination of oral etoposide, administered once a day at
 doses ranging from 40 to 60 mg/m2/day (d) for 21 consecutive days, and
 carboplatin, administered i.v. **ovr** 1 h at dose ranging from 300
 to 400 mg/m2 on day 1 to det. the appropriate doses of this combination.
 In addn., pharmacokinetic and pharmacodynamic analyses were performed.
 All the patients had a performance status of 0 to 1. Serum etoposide and
 free platinum (Pt) concns. were measured using high-performance liq.
 chromatog. and at. absorption, resp. Myelosuppression, nausea and
 vomiting were the dose limiting toxicities of the schedule. The max.
 tolerated dose (MTD) was 50 mg/m2/d oral etoposide for 21 days and 400
 mg/m2 i.v. carboplatin on day 1. For heavily pretreated patients, the

MTD

was 40 mg/m2/d oral etoposide for 21 days and 350 mg/m2 i.v. carboplatin

on

day 1. No cumulative increase in the area under the concn.-time curve
 (AUC) for oral etoposide over time was obsd. There were significant
 correlations between the free Pt serum level (6, 8, 12, 24 h post-dose)
 and etoposide AUC level (days 1, 10 and 21) for graded hematol. toxicity,

Davis 09/717,883

and the percentage decrease and nadir counts of Hb, leukocytes, neutrophils and platelets. Several pharmacodynamic models were developed to predict the hematol. toxicity. In order facilitate pharmacodynamic evaluation in future studies, a limited sampling model for oral etoposide was also developed and validated.

=> fil rég

FILE 'REGISTRY' ENTERED AT 14:37:59 ON 03 MAY 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 2 MAY 2001 HIGHEST RN 334473-38-0
DICTIONARY FILE UPDATES: 2 MAY 2001 HIGHEST RN 334473-38-0

TSCA INFORMATION NOW CURRENT THROUGH January 11, 2001

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT
for details.

=> d his

(FILE 'REGISTRY' ENTERED AT 14:36:43 ON 03 MAY 2001)

DEL HIS Y
L1 0 S OVR107
L2 2 S OVR
L3 ~~1 S 212384-33-3~~

FILE 'REGISTRY' ENTERED AT 14:37:59 ON 03 MAY 2001

=> d ide can 12

L2 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2001 ACS
RN ~~212384-33-3~~ REGISTRY
CN OVR 1 (9CI) (CA INDEX NAME)
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 129:217946

=> d ide can 12 2

L2 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2001 ACS
RN 8056-51-7 REGISTRY
CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-,
(17.alpha.)-(.+-.)-, mixt. with (17.alpha.)-19-norpregna-1,3,5(10)-trien-
20-yne-3,17-diol (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:

CN 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17.alpha.)-, mixt. contg.
(9CI)

OTHER NAMES:

CN 17.alpha.-Ethinylestradiol-norgestrel mixt.
CN Biphasil
CN dl-Norgestrel-ethinylestradiol mixt.
CN dl-Norgestrel-ethinylestradiol mixt.
CN Duoluton
CN Ediwal
CN Ethinylestradiol-dl-norgestrel mixt.
CN Ethinylestradiol-norgestrel mixt.
CN Ethinylestradiol-norgestrel mixture
CN Ethinylestradiol-dl-norgestrel mixture
CN Ethinylestradiol-norgestrel mixt.
CN Ethinylestradiol-norgestrel mixture
CN Eugynon
CN Eugynon 30
CN Femenal
CN Follimin
CN Follinett
CN Follinyl
CN Gravistat
CN Lo-Femenal
CN **Lo/Ovral**
CN Microvlar
CN Microvlar 30
CN Minidril
CN Minigynon
CN Neogynon
CN Neovletta
CN Nordiol
CN Norgestrel-ethinylestradiol mixt.
CN Orasecron
CN Ovidon
CN **Ovral**
CN **Ovral 21**
CN **Ovral 28**
CN **Ovral L**
CN Ovrán
CN Ovránette
CN Primovlar
CN Pro-Duosterone
CN Rigevidon
CN Sequilar
CN Sequilarum
CN Sequostat
CN SH 71121
CN SHB 261AB
CN SHB 264AB
CN Stediril
CN Stediril d
CN Triovlar

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for
DISPLAY

FS STEREOSEARCH

DR 8063-84-1, 8064-50-4, 70208-30-9


MF C21 H28 O2 . C20 H24 O2

CI MXS
LC STN Files: AGRICOLA, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT,
CAPLUS, CBNB, CHEMLIST, CIN, DIOGENES, EMBASE, IMSDIRECTORY, MEDLINE,
PHAR, PROMT, RTECS*, TOXLINE, TOXLIT, USPATFULL
(*File contains numerically searchable property data)

CM 1

CRN 6533-00-2
CMF C21 H28 O2


Relative stereochemistry.



CM 2

CRN 57-63-6
CMF C20 H24 O2

Absolute stereochemistry.



467 REFERENCES IN FILE CA (1967 TO DATE)
467 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:359337
REFERENCE 2: 133:84410
REFERENCE 3: 133:68916
REFERENCE 4: 133:38394
REFERENCE 5: 133:935

REFERENCE 6: 132:132773
REFERENCE 7: 130:90626
REFERENCE 8: 130:33166
REFERENCE 9: 129:286116
REFERENCE 10: 128:188700

=> d all 13

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS
RN 212384-33-3 REGISTRY
CN OVR 1 (9CI) (CA INDEX NAME)
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1

AN 129:217946 CA
TI Modeling of heat and mass transfer in intumescent fire-resistant coatings
AU Zverev, V. G.; Gol'din, V. D.; Nesmelov, V. V.; Tsimbalyuk, A. F.
CS Tomsk. Gos. Univ., Tomsk, 634050, Russia
SO Fiz. Goreniya Vzryva (1998), 34(2), 90-98
CODEN: FGVZA7; ISSN: 0430-6228
PB Izdatel'stvo Sibirskogo Otdeleniya RAN
DT Journal
LA Russian
CC 42-4 (Coatings, Inks, and Related Products)
AB Heat transfer, mass transfer, and properties of a series of intumescent
coatings was studied. Exptl. data are given on the wt. loss and degree
of swelling of these materials as a function of temp. The mechanisms of
fireproofing effect of intumescent coatings is analyzed. A math. model
is presented, which makes it possible to prognosticate the state of
fireproofed constructions after being subjected to heat stress
characteristic for fires. The theor. calcns. were in good agreement with
exptl. results obtained for steel sample.
ST intumescent fireproofing coating heat mass transfer; math model
fireproofing action intumescent coating
IT Intumescent materials
(fire-resistant coatings; modeling of heat and mass transfer in
intumescent fire-resistant coatings)
IT Fire-resistant coatings
(intumescent; modeling of heat and mass transfer in intumescent
fire-resistant coatings)

IT Heat transfer
Mass transfer
Physicochemical simulation
 (modeling of heat and mass transfer in intumescent fire-resistant
 coatings)
IT 212384-33-3, OVR 1 212384-44-6, SGK 1 (coating)
RL: PEP (Physical, engineering or chemical process); PRP (Properties);
TEM
 (Technical or engineered material use); PROC (Process); USES (Uses)
 (modeling of heat and mass transfer in intumescent fire-resistant
 coatings)
IT 12597-69-2, Steel, properties
RL: PEP (Physical, engineering or chemical process); PRP (Properties);
PROC (Process)
 (modeling of heat and mass transfer in intumescent fire-resistant
 coatings on)